Sunday, 16 August 2026European Markets
ExploreSearch
ViaNews EU
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 19, 2026

Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights

View original at finance.yahoo.com
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights Mereo BioPharma Group plc Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into mid-…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Partnering discussions around alvelestat in AATD-LD are continuing to advance on multiple fronts

    60% confidence

  • Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab in osteogenesis imperfecta are ongoing

    60% confidence

  • Setrusumab demonstrated statistically significant improvements in bone mineral density and compelling reductions in vertebral fractures

    60% confidence

  • Single Phase 3 trial enrolling approximately 220 AATD-LD patients will support regulatory submissions in both U.S. and Europe

    60% confidence

  • Existing cash and cash equivalents will enable funding of operations into mid-2027

    60% confidence

  • There are no FDA or EMA therapies approved specifically for osteogenesis imperfecta

    60% confidence

  • Data from setrusumab studies may provide basis for engagement with regulatory agencies despite missing primary endpoints

    60% confidence

  • Revised financial runway into mid-2027 enables potential delivery of several key milestones during 2026

    60% confidence

  • āshibio plans to initiate a Phase 2 trial of vantictumab in osteopetrosis in the second half of 2026

    60% confidence

  • Phase 3 Orbit and Cosmic studies did not achieve statistical significance on primary endpoints of fracture reduction

    60% confidence